Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.

Neil E. Kay

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.'. Together they form a unique fingerprint.